The immunosuppressive TME also limits the efficacy of PD‐1 blockade by restricting the infiltration and activation of tumor‐reactive T cells.[5] Our data suggest that CXCL13 CAR T cells overcome these barriers through enhanced migration and infiltration into the TME. Here, CXCL13 is linked to neoplasm.